Barr H, MacRobert A J, Tralau C J, Boulos P B, Bown S G
Department of Surgery, Rayne Institute, University College London, UK.
Br J Cancer. 1990 Nov;62(5):730-5. doi: 10.1038/bjc.1990.368.
Photodynamic therapy (PDT) depends on the interaction of light with an administered photosensitiser to produce a local cytotoxic effect. The most widely used photosensitiser is haematoporphyrin derivative (HpD), but newer photosensitisers such as aluminium sulphonated phthalocyanine (A1SPc) are promising. HpD and A1SPc have been compared as photosensitisers for colonic PDT in the rat. Quantitative analysis showed that following injection of a standard photosensitiser dose, A1SPc produced more damage than HpD with increasing energy (fluence). Alteration of the injected dose of photosensitiser did not produce a clear difference. There was a loss of reciprocity for photosensitiser/light combinations at low injected dose (0.5 mg kg-1), both HpD and A1SPc producing no damage. Similarly at high photosensitiser dosage (25 mg kg-1) there was no quantitative difference between A1SPc and HpD. Photosensitiser photodegradation at low photosensitiser doses, and light attenuation by high tissue concentrations of A1SPc account for these findings. PDT with either agent produced the same histological damage and full thickness necrosis produced no mechanical weakening of the colon measured by the bursting pressure. The submucosal collagen was preserved and healing was by regeneration.
光动力疗法(PDT)依赖于光与所给予的光敏剂之间的相互作用来产生局部细胞毒性作用。使用最广泛的光敏剂是血卟啉衍生物(HpD),但诸如磺化铝酞菁(A1SPc)等新型光敏剂也很有前景。已将HpD和A1SPc作为大鼠结肠PDT的光敏剂进行了比较。定量分析表明,注射标准剂量的光敏剂后,随着能量(光通量)增加,A1SPc比HpD产生的损伤更大。改变光敏剂的注射剂量并未产生明显差异。在低注射剂量(0.5 mg kg-1)时,光敏剂/光组合不存在互易关系,HpD和A1SPc均未产生损伤。同样,在高光敏剂剂量(25 mg kg-1)时,A1SPc和HpD之间没有定量差异。低剂量光敏剂时的光敏剂光降解以及高组织浓度的A1SPc导致的光衰减可以解释这些发现。使用任何一种药物进行PDT都会产生相同的组织学损伤,通过爆破压力测量,全层坏死并未导致结肠机械性减弱。黏膜下胶原蛋白得以保留,愈合是通过再生实现的。